Clinical Trial Search

Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients

Primary: HPV Identification — 95; 142; 78 biopsies

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants

Primary: Progression-free Survival (PFS) — 65 percentage of patients

Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants

Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11

Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells

Primary: Objective Response Rate (ORR) — 17.7 Percentage of Participants

Primary: DLT Evaluation for Safety and Tolerability(Part A) — 0 participants

Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants

Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants

Primary: Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18) — 0; 15; 0; 11 Participants

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…

Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of…

Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants

Primary: Deep Response Rate (DRR) — 16; 19 Participants

Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants

Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants

Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants

Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL

Primary: Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC). — 37 Participants